GLP-1 agonists prompt the pancreas to release insulin in a glucose-dependent manner
Contact the pharmacy or your clinician if you are unsure
BPC-157 5mg and TB-500 5mg as distributed by Peptides Lab UK are not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment
Do not freeze a reconstituted vial
Appetite Suppression: GLP-1s also impact the brains appetite-regulating centers, helping reduce hunger and promote satiety
Clinical trials have identified higher risks of gastrointestinal (GI) events such as pancreatitis, bowel obstruction, biliary disease, and gastroparesis